Abnormal Security vs BioCatch

By valuation, Abnormal Security is the larger company at $5.1B versus $1.3B — a 3.9x difference. Size can also be measured by team: Abnormal Security employs 650 people while BioCatch has 100-500 employees.

Abnormal Security has raised more in total funding at $546M, compared to BioCatch's $213M — a gap of $333M. Combined, the two companies have completed 5 known funding rounds.

It's a dead heat — both Abnormal Security and BioCatch sit at 80/100 on the Awaira Score. That score factors in valuation, funding, stage, headcount, and category.

Abnormal Security was founded by Evan Reiser in 2018. BioCatch was founded by Avi Turgeman in 2011. Visit each company's profile on Awaira for a full founder biography.

Abnormal Security: Abnormal Security is an AI-focused cybersecurity company founded in 2018 that specializes in email and cloud security. The company develops AI-powered threat detection systems designed to identify and prevent advanced email attacks, including phishing, business email compromise (BEC), and account takeover attempts. Its core platform uses behavioral AI and machine learning to analyze communication patterns and detect anomalies that traditional security tools miss. The company's technology focuses on cloud email environments, particularly Microsoft 365 and Google Workspace, where it monitors user behavior, message content, and sender patterns in real-time. Abnormal Security has achieved a valuation of $5.1 billion following Series D funding, with total funding of $546 million. The company operates in a competitive landscape alongside established vendors like Proofpoint, Mimecast, and Cisco, as well as emerging AI security startups. Its positioning emphasizes reducing security alert fatigue through AI accuracy while preventing targeted attacks that evade traditional signature-based detection. The company has secured enterprise customers across various industries, though specific customer names are not widely disclosed. Growth trajectory indicates strong market demand for AI-driven email security solutions as organizations face increasingly sophisticated social engineering attacks. Abnormal Security represents the broader shift toward behavioral AI in enterprise security infrastructure. Abnormal Security applies behavioral AI specifically to email security, addressing a historically high-friction attack vector that traditional tools struggle to defend against effectively. BioCatch: BioCatch provides behavioural biometrics and fraud prevention AI that analyses how users physically interact with digital devices — mouse movements, typing cadence, touch pressure, and navigation patterns — to authenticate genuine users and detect account takeover, social engineering, and application fraud in real time during banking and financial transactions. The Tel Aviv company processes behavioural signals from hundreds of millions of user sessions monthly, building individual profiles that flag deviations indicating fraud.\n\nThe company raised approximately $213 million in venture funding including a Series D led by Tiger Global, reaching a valuation exceeding $1 billion. BioCatch counts over 30 tier-one banks globally among its clients including American Express, NatWest, and Lloyds Banking Group, with deployments protecting online banking and mobile banking sessions from fraud that bypasses traditional authentication controls. The platform is particularly effective against malware-assisted fraud and social engineering scams where the genuine account holder is unknowingly manipulated.\n\nBioCatch competes in the behavioural biometrics and fraud intelligence market alongside ThreatMetrix (now LexisNexis Risk Solutions), Sift, and Sardine, as well as traditional fraud management platforms from FICO and SAS. Its differentiation is the depth of its behavioural feature engineering from passive interaction signals that do not require active user participation, creating a fraud layer that operates continuously without adding friction to legitimate user journeys. The growing prevalence of authorised push payment fraud and social engineering attacks in European banking has expanded the relevant use case for BioCatch beyond traditional account takeover detection.

BioCatch got there first, launching in 2011 — that's 7 years of extra runway. Abnormal Security didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Abnormal Security has about 650 employees; BioCatch has about 100-500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Abnormal Security and BioCatch compete in AI Security, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.